Key Highlights:
- Oxford Biomedica (LSE:OXB) shares fell 3.23% to 509p on 24 August 2026, on relatively light trading volume.
- This follows a sharper 17.6% fall on 7 August 2026 after a cut to full-year 2026 Revenue guidance.
- Full-year revenue guidance was cut to £180m–£200m from a prior £220m–£240m range.
- The company signed 17 new client contracts in H1 2026, exceeding all of 2025’s total by around 30%.
- A six-month delay to the Durham, North Carolina Manufacturing Facility was the primary driver of the guidance cut.
Oxford BioMedica (LSE:OXB), the Oxford-based cell and gene therapy contract development and manufacturing organisation (CDMO), fell 3.23% to 509p on 24 August 2026, putting it among the day's biggest London-listed decliners per available market data. The stock carries no meaningful trailing price/earnings ratio — shown as "—" in snapshot data — reflecting a trailing twelve-month loss per share of 0.28 GBP, even as trailing EPS growth is recorded at a positive 31.72%, indicating the scale of losses has been narrowing year-on-year. At a Market Capitalisation of £636.57m, Oxford Biomedica remains one of the more prominent UK-listed names in the advanced-therapies manufacturing space, supplying viral vector production services to biotech and pharmaceutical clients developing gene and cell therapies.
The 24 August fall follows a much larger, confirmed share-price shock earlier in the month: on 7 August 2026, Oxford Biomedica's shares fell sharply — reported at around 17.6% lower on the day, to roughly 486.9p — after the company published half-year results alongside a cut to its full-year 2026 revenue guidance. This article treats that 7 August event as important recent context for understanding the stock's current trading range, while being clear that the smaller 24 August move is a separate, later data point for which no new specific catalyst was identified in this review.
The August Guidance Cut — What Happened
According to reporting on the 7 August 2026 announcement, Oxford Biomedica delivered revenue growth of approximately 9% in the first half of 2026, taking half-year revenue to roughly £80m. Despite that growth, the company cut its full-year 2026 revenue guidance to a range of £180m-£200m, down from a prior guidance range reported as £220m-£240m. Management attributed the reduction to deferrals and delayed programmes — described elsewhere as client ordering changes, including a shift in procurement strategy by a major client — and a reported six-month delay to the operational readiness of the company's Durham, North Carolina manufacturing facility in the United States.
Despite the guidance cut, the company reportedly pointed to continued underlying commercial momentum, citing 17 new client contract signings in the first half of 2026 — said to exceed the whole of 2025's total by around 30%. Management reiterated a longer-term growth ambition: 25-30% year-on-year revenue growth targeted for 2027, and an ambition to reach approximately £500m in revenue by 2030, alongside a goal of achieving double-digit EBITDA margins as the Business scales.
available market data placed Oxford Biomedica's share price at 509p as of 24 August 2026, with Volume of 285,690 shares changing hands that day but relative volume of only 0.42 times the recent average — suggesting the 24 August move, while notable in percentage terms, occurred on relatively light trading activity compared with the heavier volumes likely seen around the 7 August results and guidance revision. The absence of a P/E ratio reflects the company's continued net losses on a trailing basis, a common feature of clinical-and-manufacturing-stage biotech and advanced therapy businesses that are investing heavily in capacity ahead of full commercial-scale profitability.
Financial Performance in Context
Oxford Biomedica (LSE:OXB)'s business model centres on providing viral vector manufacturing and development services — critical infrastructure for gene and cell therapy developers, including well-known partners in the sector. Revenue growth of roughly 9% in H1 2026 demonstrates continued client demand, even as the guidance cut shows that revenue recognition can be lumpy and dependent on the timing of individual client manufacturing campaigns and facility readiness. The trailing EPS growth of +31.72% recorded in the available market data, despite an ongoing loss position, suggests the pace of losses narrowing has been a feature of the stock's recent trajectory — consistent with a business scaling toward profitability but not yet there.
Strategic and Operational Developments
The reported delay to the Durham, North Carolina facility is a material operational detail: US manufacturing capacity has been a strategic priority for Oxford Biomedica as it seeks to serve American biotech and pharma clients closer to home and diversify beyond its UK manufacturing base. A six-month delay to that facility's readiness has direct near-term revenue implications, consistent with the scale of the guidance cut. The company's continued new client signings, however, point to sustained Demand for outsourced viral vector manufacturing capacity across the industry.
The cell and gene therapy sector has experienced a challenging funding and commercialisation environment over the past several years, with biotech financing conditions affecting the pace at which developer clients can commission and pay for manufacturing services. CDMOs like Oxford Biomedica sit Downstream of that funding cycle: when client biotechs delay programmes or renegotiate manufacturing schedules, contract manufacturers can see guidance Volatility even when underlying long-term demand for advanced therapy manufacturing remains intact. Industry-wide, viral vector manufacturing capacity remains a bottleneck for gene therapy commercialisation, which underpins the sector's structural growth narrative even amid near-term order timing volatility.
Bulls point to continued double-digit revenue growth, a record pace of new client signings, narrowing losses, and long-term guidance (25-30% growth in 2027, ~£500m revenue by 2030 with double-digit EBITDA margins) that remains intact despite the near-term cut. The essential, infrastructure-like nature of viral vector manufacturing for the broader gene and cell therapy industry supports a structural growth case once capacity constraints such as the Durham delay are resolved.
Bears will point to the scale of the guidance cut — a roughly 15-18% reduction at the midpoint of full-year revenue guidance — as evidence of forecasting and execution risk, particularly around facility readiness timelines and reliance on a concentrated client base whose ordering patterns can shift. The lack of near-term profitability (no meaningful trailing P/E) and continued losses per share leave the stock dependent on continued top-line delivery to justify its market capitalisation.
Investors will likely watch for: updates on Durham facility commissioning progress; further client contract signings; any additional guidance revisions ahead of full-year results; and broader biotech funding sentiment, which affects Oxford Biomedica's client base's ability to commission manufacturing campaigns.
Oxford Biomedica's 24 August fall adds to a period of share-price volatility that began in earnest with the 7 August guidance cut. The confirmed facts show a business still growing revenue and narrowing losses, but facing real near-term execution risk around US facility readiness and client order timing. Whether the broader cell-and-gene therapy manufacturing recovery narrative remains intact will likely hinge on how quickly the company can resolve the Durham delay and convert its strong pipeline of new client signings into recognised revenue.






Please wait processing your request...